Clinical trials: Autologous Blood Transfusion
β-thalassemia Major
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector…
- Trial name
- NCT05776173
- Testing
- BD211
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Transfusion Related Complication
S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion
The Purpose of the study is to test the hypothesis that administration of an S-nitrosylating (SNO) agent can improve tissue oxygenation during transfusion of packed red blood cells (RBCs).
- Trial name
- NCT03999229
- Testing
- SNO, Normal Saline, Red Blood Cell
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- James Reynolds
Heart Transplantation
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
The investigators developed a protocol to isolate Treg cells from thymic tissue (thyTreg) discarded in pediatric cardiac surgeries.
- Trial name
- THYTECH (NCT04924491)
- Testing
- Autologous thyTreg
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Rafael Correa-Rocha
Non-Small Cell Lung Cancer
CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer
Lung cancer is the most common cancer worldwide, non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancer cases, which is the leading cause of cancer mortality, and adenocarcinoma is the most prevalent subtype.
- Trial name
- NCT01871480
- Testing
- Group A:cytokine-induced killer cell +gefitinib, Group B:Gefitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Kunming Medical University
Cirrhosis, Liver
Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis
Though the results of autologous CD34+ cell infusion and MSC in independent studies have shown promise, yet they are yet to reach the desired long term outcome.
- Trial name
- NCT04243681
- Testing
- CD 34 and MSC infusion, Standard of care for Cirrhosis management
- Where
- India
- Volunteers
- 5 people
- Sponsor
- Asian Institute of Gastroenterology, India
Coxarthrosis
Effects of the Sangvia Blood Collection System on Postoperative Infections in Orthopedic Patients
The purpose of this study is to compare the infection rate in patients receiving/not receiving their own blood, collected during surgery, during and after orthopedic surgery.
- Trial name
- NCT01725724
- Testing
- Autologous blood transfusion, Allogeneic blood transfusion
- Where
- 4 sites in Norway
- Volunteers
- 162 people
- Sponsor
- Haukeland University Hospital
Arthroplasty Complications, Total Knee Arthroplasty
Is Self-transfusion Safe After Total Knee Arthroplasty in Terms of Nephrotoxicity of Gentamicin From Bone Cement?
Considering that the high local concentration of antibiotic from bone cement is delivered intravenously through the self-transfusion process, systematic toxicity has never been evaluated.
- Trial name
- NCT04505748
- Testing
- Self-transfusion device
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- University Hospital, Alexandroupolis